0000000000105889

AUTHOR

Tai Pham

showing 20 related works from this author

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG …

2017

Background Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). Methods LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non…

MaleARDSdemographyeconomicmedicine.medical_treatmentTerapéuticaair conditioningComorbidityintensive care unitdeveloped country0302 clinical medicineneuromuscular blockingmiddle agedacute myocardial-infarctionmiddle income countryProspective StudiesGeography Medicalcritically-ill patientsadultagedpriority journalrisk factorIncomegeographic-variationDeveloped countryhospitalizationprospective studyHumanPulmonary and Respiratory MedicineDeveloped Countriemedicine.medical_specialtyDeveloping countryArticle/dk/atira/pure/subjectarea/asjc/2700/274003 medical and health sciencesSíndrome respiratorio agudo graveunitsMedicalHumansIntensive care medicineDeveloping CountriesAgedhigh income countryRespiratory Distress Syndrome Adultnoninvasive ventilationAparato respiratoriomedicine.diseasemortalitymajor clinical studyProspective Studiearterial oxygen tension030228 respiratory systemARDSObservational studySociologíahealth care deliverygeographyintensive-careRisk FactorsEpidemiologyProspective cohort studyRespiratory Distress Syndromepartial pressureartificial ventilationSociología médicaMiddle Agedadult respiratory distress syndromeAged; Comorbidity; Delivery of Health Care; Developed Countries; Developing Countries; Europe; Female; Geography Medical; Humans; Income; Intensive Care Units; Male; Middle Aged; Patient Outcome Assessment; Prospective Studies; Respiratory Distress Syndrome Adult; Risk Factors; Pulmonary and Respiratory MedicineEuropeIntensive Care UnitsfemaleincomeFemaleEnfermedadinjurycohort analysigross national incomesurvivalNOmedical geographyDeveloping Countrielength of staymedicinecontrolled studyoutcome assessmentbreast-cancerMechanical ventilationdiseasebusiness.industryDeveloped Countriespatient caredeveloping country030208 emergency & critical care medicinestatistics and numerical data AgedComorbiditywinterACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS; GEOGRAPHIC-VARIATION; INTENSIVE-CARE; BREAST-CANCER; MORTALITY; DISEASE; INJURY; UNITS; HOSPITALIZATIONPatient Outcome AssessmentEmergency medicineprone positiontreatment outcomebusinessDelivery of Health Care
researchProduct

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome: Insights from the LUNG SAFE study

2020

Abstract Background Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence o…

ARDSmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineHyperoxemiaHypoxemialaw.inventionHypoxemia0302 clinical medicinelawFraction of inspired oxygenOxygen therapyPrevalenceMedicineHypoxiaAcute respiratory distress syndrome; Hyperoxemia; Hyperoxia; Hypoxemia; Hypoxia; Invasive mechanical ventilation; Mortality; Oxygen therapy;Respiratory Distress SyndromeHyperbaric OxygenationAcute respiratory distress syndromeRespirationlcsh:Medical emergencies. Critical care. Intensive care. First aidHyperoxemiaIntensive care unitIntensive Care UnitsAnesthesiaArtificialmedicine.symptomHumanArtificial ventilationAcute respiratory distress syndrome; Hyperoxemia; Hyperoxia; Hypoxemia; Hypoxia; Invasive mechanical ventilation; Mortality; Oxygen therapyIntensive Care UnitHyperoxiaNO03 medical and health sciencesIntensive careSettore MED/41 - ANESTESIOLOGIAHumansInvasive mechanical ventilationMortalitybusiness.industryResearchRespiratory Distress Syndrome Adultlcsh:RC86-88.9medicine.diseaseOxygen therapyRespiration Artificialrespiratory tract diseasesOxygenlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]030228 respiratory systembusiness
researchProduct

Additional file 12: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S8. Patientsâ characteristics and clinical endpoints of immunocompromised (study) patients, according to the cause of immunosuppression (known, unknown). (PDF 79Â kb)

fungi
researchProduct

Additional file 11: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S7. Patient characteristics and clinical endpoints of immunocompetent patients, according to the type of ventilatory support. (PDF 88Â kb)

body regionsnervous systemfungi
researchProduct

Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute resp…

2022

Contains fulltext : 252214.pdf (Publisher’s version ) (Open Access) BACKGROUND: Geoeconomic variations in epidemiology, the practice of ventilation, and outcome in invasively ventilated intensive care unit (ICU) patients without acute respiratory distress syndrome (ARDS) remain unexplored. In this analysis we aim to address these gaps using individual patient data of four large observational studies. METHODS: In this pooled analysis we harmonised individual patient data from the ERICC, LUNG SAFE, PRoVENT, and PRoVENT-iMiC prospective observational studies, which were conducted from June, 2011, to December, 2018, in 534 ICUs in 54 countries. We used the 2016 World Bank classification to defi…

MaleSociodemographic FactorsRespiration Artificial/methodsARDS ; mechanical ventilationSeverity of Illness IndexNOSettore MED/41 - ANESTESIOLOGIA80 and overTidal VolumeHumansHospital MortalityProspective Studiesddc:610Developing CountriesAgedHospital Mortality/trendsAged 80 and overDeveloped Countries/statistics & numerical dataDeveloping Countries/statistics & numerical dataRespirationDeveloped CountriesArticlesGeneral Medicineacute respiratory distress syndromeLength of StayMiddle AgedRespiration ArtificialIntensive Care UnitsObservational Studies as Topiclnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Length of Stay/statistics & numerical dataArtificialIntensive Care Units/statistics & numerical dataIncomeFemaleARDS
researchProduct

Additional file 8: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Figure S2. This figure shows a Kaplan-Meier curve for hospital survival of immunocompromised patients according to the ventilation subgroup. This figure shows a Kaplan-Meier curve for hospital survival of immunocompromised patients according to the ventilation subgroup. Mortality is defined as mortality at hospital discharge or at 90Â days after onset of acute hypoxemic respiratory failure, whichever event occurred first. We assumed that patients discharged alive from the hospital before 90Â days were alive on day 90. Type of ventilator support: IMV Patients invasively ventilated from day 1, independently of the type of support received after the eventual extubation; NIV Patients treated ex…

researchProduct

Additional file 4: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S3. Ventilator settings during the first day of ARDS in the immunocompetent (Control) and immunocompromised (Study) groups. This table shows ventilator settings during the first day of ARDS in the immunocompetent (Control) and immunocompromised (Study) groups. (PDF 50Â kb)

researchProduct

Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE)

2023

Background: Current management practices and outcomes in weaning from invasive mechanical ventilation are poorly understood. We aimed to describe the epidemiology, management, timings, risk for failure, and outcomes of weaning in patients requiring at least 2 days of invasive mechanical ventilation. Methods: WEAN SAFE was an international, multicentre, prospective, observational cohort study done in 481 intensive care units in 50 countries. Eligible participants were older than 16 years, admitted to a participating intensive care unit, and receiving mechanical ventilation for 2 calendar days or longer. We defined weaning initiation as the first attempt to separate a patient from the ventila…

Pulmonary and Respiratory MedicineInternal Medicine SciencesKlinik TıpRESPIRATORY SYSTEMDahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINESağlık BilimleriClinical Medicine (MED)TıpSOLUNUM SİSTEMİMechanical ventilationN/AHealth SciencesSettore MED/41 - ANESTESIOLOGIAAkciğer ve Solunum TıbbıMedicineKlinik Tıp (MED)Chest Diseases and AllergyThe Lancet Respiratory Medicine
researchProduct

Additional file 2: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S1. Patient characteristics of immunocompromised patients according to the type of ventilator support. This table shows patient characteristics, including comorbidities, ARDS risk factors, and illness severity at ARDS onset of immunocompromised patients according to the type of ventilator support. (PDF 74Â kb)

researchProduct

Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

2017

biologybusiness.industry030208 emergency & critical care medicineLymphocyte proliferationCritical Care and Intensive Care MedicineMeeting Abstractslaw.invention03 medical and health sciencesInterleukin 100302 clinical medicine030228 respiratory systemlawPD-L1ImmunologyPostoperative infectionCardiopulmonary bypassbiology.proteinMedicine030212 general & internal medicinebusinessAnnals of Intensive Care
researchProduct

Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database

2018

Background: The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiog…

MaleARDSmodelos logísticosDatabases Factualmedicine.medical_treatment[SDV]Life Sciences [q-bio]humanoslnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Kaplan-Meier EstimateCritical Care and Intensive Care MedicineAcute respiratory failureSeverity of Illness IndexCohort Studiesrandomized-trial0302 clinical medicineMechanical ventilationRisk Factorsestudios prospectivosEpidemiology80 and overicuMedicineProspective StudiesProspective cohort studyestudios de cohortesImmunodeficiencymediana edadestadísticasAged 80 and overRespiratory Distress Syndromeancianocritically-ill patientsRespirationresultado del tratamientorespiraciónStatisticslcsh:Medical emergencies. Critical care. Intensive care. First aidadultoMiddle Aged3. Good healthfailureIntensive Care UnitsTreatment OutcomeArtificialCohortprospective multicenterImmunocompromised patientsAcute respiratory failure; ARDS; Immunocompromised patients; Mechanical ventilation; Noninvasive ventilation; Critical Care and Intensive Care MedicineFemaleNoninvasive ventilationHumanestimación de Kaplan-MeierAdultmedicine.medical_specialtyLogistic ModelIntensive Care UnitSocio-culturaleunidades de cuidados intensivossurvivalStatistics NonparametricSepsisDatabases03 medical and health sciencesImmunocompromised HostInternal medicineImmunocompromised patientcancerfactores de riesgoHumansNonparametricíndice de gravedad de la enfermedadintensive-care-unitFactualAgedMechanical ventilationbusiness.industryResearchRisk FactorRespiratory Distress Syndrome Adult030208 emergency & critical care medicinelcsh:RC86-88.9medicine.diseaseRespiration ArtificialPneumoniaProspective StudieLogistic Models030228 respiratory systemmalignanciesARDShuésped inmunodeprimidoCohort StudiebusinessAcute respiratory failure; ARDS; Immunocompromised patients; Mechanical ventilation; Noninvasive ventilation; Adult; Aged; Aged 80 and over; Cohort Studies; Databases Factual; Female; Humans; Intensive Care Units; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Prospective Studies; Respiration Artificial; Respiratory Distress Syndrome Adult; Risk Factors; Severity of Illness Index; Statistics Nonparametric; Treatment Outcome; Immunocompromised Host
researchProduct

Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective …

2022

Item does not contain fulltext BACKGROUND: Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct clinical and biological features and differential treatment responses have been identified using latent class analysis (LCA) in seven individual cohorts. To facilitate bedside identification of subphenotypes, clinical classifier models using readily available clinical variables have been described in four randomised controlled trials. We aimed to assess the performance of these models in observational cohorts of ARDS. METHODS: In this observational, multicohort, retrospective study, we validated two machine-learning clinical classifie…

Pulmonary and Respiratory MedicineClinical SciencesAcute Lung InjuryArticleMachine LearningPositive-Pressure RespirationRare DiseasesClinical ResearchRetrospective StudieSettore MED/41 - ANESTESIOLOGIAHumansLungAcute Respiratory Distress SyndromeRetrospective StudiesRespiratory Distress SyndromeOther Medical and Health SciencesLUNG SAFE Investigators and the ESICM Trials Grouplnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]PhenotypeGood Health and Well BeingArea Under CurveARDS: PhenotypeRespiratoryPublic Health and Health ServicesARDSHuman
researchProduct

Additional file 6: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S6. Ventilator settings during the first day of ARDS in immunocompetent (Control) and immunocompromised (Study) patients, stratified by the type of ventilatory support (IMV, NIV, NIV failure). (PDF 60Â kb)

researchProduct

Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome: Insights from the LUNG SAFE Study

2016

Rationale: Noninvasive ventilation (NIV) is increasingly used in patients with acute respiratory distress syndrome (ARDS). The evidence supporting NIV use in patients with ARDS remains relatively sparse.Objectives: To determine whether, during NIV, the categorization of ARDS severity based on the PaO2/FiO2 Berlin criteria is useful.Methods: The LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of patients with ARDS. This substudy examines the current practice of NIV use in ARDS, the utility of the PaO2/FiO2 ratio in classifying patients receiving NIV, and the impact of NIV on outcome.Measurements and Main…

MaleARDSprocedureblood oxygen tensionCritical Care and Intensive Care MedicineSeverity of Illness Indexlaw.invention0302 clinical medicinelawHospital MortalityRespiratory Distress SyndromeAcute respiratory distress syndromeadult respiratory distress syndromeMiddle AgedIntensive care unitIntensive Care Unitsmedicine.anatomical_structureTreatment Outcomepriority journalpositive end expiratory pressureNoninvasive ventilationdisease severityFemaletreatment outcome AgedNoninvasive ventilationprospective studyHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtycohort analysiIntensive Care Unitdisease classificationAcute respiratory distressArticleNO03 medical and health sciencesacute respiratory distress syndrome; noninvasive ventilationlength of staySeverity of illnessSettore MED/41 - ANESTESIOLOGIAmedicineSequential Organ Failure Assessment ScoreHumansIn patientAcute respiratory distress syndrome; Noninvasive ventilation; Aged; Female; Hospital Mortality; Humans; Intensive Care Units; Male; Middle Aged; Respiratory Distress Syndrome Adult; Severity of Illness Index; Treatment Outcome; Noninvasive Ventilation; Pulmonary and Respiratory Medicine; Critical Care and Intensive Care MedicineIntensive care medicineoutcome assessmentAgedLungbusiness.industryRespiratory Distress Syndrome Adult030208 emergency & critical care medicinemedicine.diseasemajor clinical studymortalityrespiratory tract diseasesbreathing ratemulticenter study030228 respiratory systemincidenceObservational studyobservational studybusinessAcute respiratory distress syndrome; Noninvasive ventilation;
researchProduct

Additional file 1: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

List of LUNG SAFE investigators. Names and affiliations of the LUNG SAFE investigators. (PDF 172Â kb)

body regionsnervous systemfungirespiratory systemrespiratory tract diseases
researchProduct

Additional file 7: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Figure S1. Kaplan-Meier curve for hospital survival in immunocompromised patients according to ARDS severity. Kaplan-Meier curve for hospital survival in immunocompromised patients according to ARDS severity. Mortality is defined as mortality at hospital discharge or at 90Â days after onset of acute hypoxemic respiratory failure, whichever event occurred first. We assumed that patients discharged alive from the hospital before 90Â days were alive on day 90. Severity of ARDS was evaluated at the day of onset according to the Berlin definition. Note: The number of patients reported in the bottom of figure is referred to as the end of the corresponding day. (PDF 402Â kb)

researchProduct

Additional file 3: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S2. Factors associated with the use of noninvasive ventilation. Multivariate logistic regression model describing the factors associated with the use of noninvasive ventilation. (PDF 49Â kb)

researchProduct

Additional file 10: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S9. The most important factors leading to death in the ICU in immunocompetent and immunocompromised patients. (PDF 44Â kb)

body regionsnervous systemfungi
researchProduct

Additional file 5: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S4. Adjunctive measures/therapies during at least one day during follow-up in immunocompetent and immunocompromised patients. This table shows the proportions of adjunctive measures/therapies during at least one day during follow-up in immunocompetent and immunocompromised patients. (PDF 97Â kb)

researchProduct

Additional file 9: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

2018

Table S5. Factors associated with hospital mortality in immunocompromised patients. Multivariate logistic regression model describing the factors associated with hospital mortality in immunocompromised patients. (PDF 49Â kb)

researchProduct